Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 1/20 | 0.43 |
| ▸ | HEXB | P07686 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512916 | 1.00 | HEXA (0.43) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL8609589 | 0.89 | HEXA (0.42) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL31054315 | 0.88 | HEXA (0.47) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL29386112 | 0.87 | HEXA (0.41) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL9687962 | 0.87 | HEXA (0.41) | HEXAHEXBCYP3A4TSHRNPC1 | |
| Hydrochloric Acid SCHEMBL8740059 | 0.85 | CYP3A4 (0.41) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL28844141 | 0.80 | TSHR (0.47) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL367477 | 0.79 | CD44 (0.39) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL8361077 | 0.78 | CD44 (0.52) | HEXAHEXBCYP3A4TSHRNPC1 | |
| SCHEMBL1133067 | 0.78 | MYC (0.56) | HEXAHEXBCYP3A4TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-115557907-A | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115279766-A | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114921391-A | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110023302-B | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-110248937-B | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3818063-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3194380-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194381-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042080-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042081-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-9266913-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | HEXA 3097/4885HEXB 2400/4885CYP3A4 1076/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | HEXA 3097/4885HEXB 2400/4885CYP3A4 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.